<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627899</url>
  </required_header>
  <id_info>
    <org_study_id>3091611</org_study_id>
    <nct_id>NCT01627899</nct_id>
  </id_info>
  <brief_title>One Touch VerioIQ US Clinical Outcomes Study</brief_title>
  <official_title>One Touch VerioIQ US Clinical Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeScan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LifeScan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical benefits of One Touch VerioIQ system
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains
      pattern alert technology and comes with educational material (Pattern guide) which provides
      additional support and insights to patients and health care providers to help them make more
      informed decisions during blood glucose management.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision to terminate trial
  </why_stopped>
  <start_date type="Actual">October 1, 2012</start_date>
  <completion_date type="Actual">July 1, 2013</completion_date>
  <primary_completion_date type="Actual">May 1, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1C From Baseline to Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in A1C from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in A1C From Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in A1C from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG From Baseline to 24 Weeks and Over Time</measure>
    <time_frame>24 weeks and over time</time_frame>
    <description>Change in Fasting Plasma Glucose (FPG) from baseline to 24 weeks and over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proportion of Subjects With A1C Less Than or Equal to 7.0% at Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>VerioIQ</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects replaced own Blood Glucose Monitoring system with VerioIQ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>One Touch VerioIQ Blood Glucose Monitor</intervention_name>
    <description>BGM with pattern alert technology and with associated pattern guide</description>
    <arm_group_label>VerioIQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female at least 18 to 80 years old

          -  ADA guidelines for FPG and PPG appropriate

          -  A1C greater or equal to 8.0% and less than or equal to 10.5%

          -  lab A1C greater than or equal to 8.0% in the last 6-12mths

          -  Diagnosed with type 1 or 2 in at least last 1 year

          -  on stable dose of OADs for at least 3mths prior to screening

          -  willingness to test 7 BGM tests per day

          -  willing to remain on same therapy as baseline (MDI) for duration of study

        Exclusion Criteria:

          -  unlikely to be compliant to study procedures

          -  has or has currently used One Touch VerioIQ

          -  Is on fixed doses of insulin for MDI therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscilla Hollander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Endocrine Center, 3600 Gaston Avenue Wadley Tower, Suite 656, Dallas, TX 75246, Phone: 214-820-3466, Fax: 214-820-3468</affiliation>
  </overall_official>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>July 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2018</results_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood glucose monitor</keyword>
  <keyword>Pattern management</keyword>
  <keyword>Pattern guide</keyword>
  <keyword>Education</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At medical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>OneTouch VerioIQ BGMS</title>
          <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated early by sponsor.</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No data was analysed including demographics as study was terminated early before any data was collected.</population>
      <group_list>
        <group group_id="B1">
          <title>OneTouch VerioIQ BGMS</title>
          <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>No data was analysed including demographics as study was terminated early before any data was collected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <population>No data was analysed including demographics as study was terminated early before any data was collected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in A1C From Baseline to Week 24</title>
        <description>Change in A1C from baseline to week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Study terminated early by sponsor, no analysis completed.</population>
        <group_list>
          <group group_id="O1">
            <title>OneTouch VerioIQ BGMS</title>
            <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
          </group>
        </group_list>
        <measure>
          <title>Change in A1C From Baseline to Week 24</title>
          <description>Change in A1C from baseline to week 24</description>
          <population>Study terminated early by sponsor, no analysis completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in A1C From Baseline to Week 12</title>
        <description>Change in A1C from baseline to week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Study terminated early by sponsor, no analysis completed.</population>
        <group_list>
          <group group_id="O1">
            <title>OneTouch VerioIQ BGMS</title>
            <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
          </group>
        </group_list>
        <measure>
          <title>Change in A1C From Baseline to Week 12</title>
          <description>Change in A1C from baseline to week 12</description>
          <population>Study terminated early by sponsor, no analysis completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG From Baseline to 24 Weeks and Over Time</title>
        <description>Change in Fasting Plasma Glucose (FPG) from baseline to 24 weeks and over time</description>
        <time_frame>24 weeks and over time</time_frame>
        <population>Study terminated early by sponsor, no analysis completed.</population>
        <group_list>
          <group group_id="O1">
            <title>OneTouch VerioIQ BGMS</title>
            <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG From Baseline to 24 Weeks and Over Time</title>
          <description>Change in Fasting Plasma Glucose (FPG) from baseline to 24 weeks and over time</description>
          <population>Study terminated early by sponsor, no analysis completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Proportion of Subjects With A1C Less Than or Equal to 7.0% at Week 24</title>
        <time_frame>24 weeks</time_frame>
        <population>Study terminated early by sponsor, no analysis completed.</population>
        <group_list>
          <group group_id="O1">
            <title>OneTouch VerioIQ BGMS</title>
            <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proportion of Subjects With A1C Less Than or Equal to 7.0% at Week 24</title>
          <population>Study terminated early by sponsor, no analysis completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks</title>
        <time_frame>24 weeks</time_frame>
        <population>Study terminated early by sponsor, no analysis completed.</population>
        <group_list>
          <group group_id="O1">
            <title>OneTouch VerioIQ BGMS</title>
            <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks</title>
          <population>Study terminated early by sponsor, no analysis completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OneTouch VerioIQ BGMS</title>
          <description>Subjects replaced own Blood Glucose Monitoring system (BGMS) with OneTouch VerioIQ</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No data was analysed as study was terminated early before any data was collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mike Grady</name_or_title>
      <organization>LifeScan Scotland</organization>
      <phone>+44 01463 721000</phone>
      <email>MGRADY@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

